DURECT Corporation (DRRX) Cut to Hold at Stifel Nicolaus
DURECT Corporation (NASDAQ:DRRX) was downgraded by analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating in a research report issued on Friday, Marketbeat Ratings reports.
Several other research firms also recently weighed in on DRRX. ValuEngine raised shares of DURECT Corporation from a “sell” rating to a “hold” rating in a research note on Tuesday, September 26th. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price target on shares of DURECT Corporation in a research note on Sunday, June 25th.
DURECT Corporation (DRRX) opened at 0.8914 on Friday. The company has a 50-day moving average of $1.74 and a 200-day moving average of $1.47. The firm’s market capitalization is $131.03 million. DURECT Corporation has a 52 week low of $0.74 and a 52 week high of $2.17.
DURECT Corporation (NASDAQ:DRRX) last posted its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.02). DURECT Corporation had a negative net margin of 221.01% and a negative return on equity of 629.35%. The company had revenue of $4.32 million during the quarter, compared to the consensus estimate of $5.17 million. On average, equities analysts forecast that DURECT Corporation will post ($0.21) earnings per share for the current fiscal year.
Large investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC bought a new stake in shares of DURECT Corporation during the first quarter worth about $118,000. Voya Investment Management LLC increased its position in shares of DURECT Corporation by 22.8% during the second quarter. Voya Investment Management LLC now owns 82,826 shares of the specialty pharmaceutical company’s stock worth $129,000 after acquiring an additional 15,394 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of DURECT Corporation during the first quarter worth about $147,000. State of Wisconsin Investment Board bought a new stake in shares of DURECT Corporation during the second quarter worth about $151,000. Finally, The Manufacturers Life Insurance Company increased its position in shares of DURECT Corporation by 12.1% during the second quarter. The Manufacturers Life Insurance Company now owns 120,977 shares of the specialty pharmaceutical company’s stock worth $189,000 after acquiring an additional 13,072 shares in the last quarter. 45.90% of the stock is owned by institutional investors.
About DURECT Corporation
Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.
Receive News & Ratings for DURECT Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT Corporation and related companies with MarketBeat.com's FREE daily email newsletter.